AIKI AIkido Pharma Inc. Stock Quote

AIKI [NASD]

Index	-	P/E	-	EPS (ttm)	-1.28	Insider Own	0.23%	Shs Outstand	5.25M	Perf Week	2.57%
Market Cap	30.49M	Forward P/E	-	EPS next Y	-2.21	Insider Trans	0.00%	Shs Float	5.03M	Perf Month	18.28%
Income	-6.70M	PEG	-	EPS next Q	-0.68	Inst Own	8.00%	Short Float	0.46%	Perf Quarter	-21.70%
Sales	-	P/S	-	EPS this Y	80.20%	Inst Trans	-6.00%	Short Ratio	0.19	Perf Half Y	-41.02%
Book/sh	18.10	P/B	0.33	EPS next Y	0.00%	ROA	-6.30%	Target Price	34.00	Perf Year	-63.43%
Cash/sh	13.48	P/C	0.44	EPS next 5Y	-	ROE	-6.70%	52W Range	4.30 - 17.17	Perf YTD	-39.97%
Dividend	-	P/FCF	-	EPS past 5Y	-14.90%	ROI	-	52W High	-65.11%	Beta	1.45
Dividend %	-	Quick Ratio	110.80	Sales past 5Y	-	Gross Margin	-	52W Low	39.30%	ATR	0.37
Employees	4	Current Ratio	110.80	Sales Q/Q	-	Oper. Margin	-	RSI (14)	58.73	Volatility	6.42% 7.52%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	39.80%	Profit Margin	-	Rel Volume	0.88	Prev Close	5.90
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	121.30K	Price	5.99
Recom	2.00	SMA20	10.69%	SMA50	8.71%	SMA200	-34.99%	Volume	106,201	Change	1.53%

Jun-28-22 09:00AM	AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements PR Newswire -5.70%
Jun-24-22 09:00AM	AIkido Inc. Announces the Formation of a New Financial Services Subsidiary PR Newswire
Jun-21-22 04:30PM	Significant Investor in AIkido Pharma Urges Board to Commit to Sell Assets and Return Capital to Stockholders GlobeNewswire
Jun-10-22 04:15PM	AIkido Pharma Inc. Appoints New Director, Soo Yu PR Newswire
Jun-07-22 04:30PM	Significant Investor in AIkido Pharma Issues Open Letter to Board of Directors GlobeNewswire +9.77%
Jun-03-22 04:30PM	AIkido Announces Reverse Stock Split PR Newswire
May-19-22 08:30AM	AIkido Pharma Announces Company Commitment to Board Diversity PR Newswire
May-12-22 03:40PM	AIkido Pharma Secures Interest in Databricks Inc. PR Newswire
May-11-22 07:10AM	AIkido Pharma (NASDAQ:AIKI) Is In A Good Position To Deliver On Growth Plans Simply Wall St. -11.56%
May-05-22 09:45AM	AIkido Reports Slinger Bag Inc.'s Filing for Nasdaq Public Listing PR Newswire -24.34%
May-04-22 03:29PM	AIkido Pharma Announces Strategic Investment in Social Communications Platform Provider Discord, Inc. PR Newswire +30.05%
Apr-22-22 10:00AM	Glass Lewis Proxy Paper Report Recommends "FOR" AIkido Pharma Inc. Proposed Reverse Stock Split PR Newswire
Apr-05-22 02:00PM	AIkido Pharma Announces Strategic Investment in MasterClass PR Newswire
Mar-11-22 10:00AM	Cedars-Sinai Medical Center and AIkido Pharma Inc. to Codevelop Novel Immuno-Oncology Cancer Treatment PR Newswire
Mar-08-22 01:30PM	Cedars-Sinai Medical Center and AIkido Pharma Inc. Enter Into Master Collaboration Agreement PR Newswire +6.39%
Mar-03-22 10:00AM	AIkido Pharma Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug PR Newswire
Mar-02-22 05:09PM	AIkido Pharma Inc. Announces Closing of $22 Million Registered Direct Offering PR Newswire
Feb-25-22 08:00AM	AIkido Pharma Inc. Announces $22 Million Registered Direct Offering PR Newswire -5.02%
Jan-24-22 01:30PM	AIkido Pharma Announces Share Repurchase Program PR Newswire
Jan-05-22 10:00AM	AIkido Pharma Announces Dr. Rachel Yehuda's Appearance on CBS News PR Newswire
Dec-14-21 10:00AM	AIkido Pharma Reports Filing for Expanded Worldwide Patent Coverage on Key Assets PR Newswire
Dec-06-21 10:00AM	AIkido Pharma Announces Strategic Interest in ASP Isotopes Inc. PR Newswire
Dec-02-21 04:24AM	We're Hopeful That AIkido Pharma (NASDAQ:AIKI) Will Use Its Cash Wisely Simply Wall St.
Nov-12-21 09:50AM	/C O R R E C T I O N -- AIkido Pharma Inc./ PR Newswire
Sep-28-21 10:45AM	AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd PR Newswire +11.35%
Sep-20-21 09:00AM	AIkido Pharma Secures Interest in Growing Tele-health Company PR Newswire -5.33%
Sep-14-21 09:22AM	AIkido Pharma Releases Shareholder Update; Near Term Catalysts Approaching PR Newswire
Aug-06-21 10:00AM	AIkido Provides Update on Use of Machine Learning in Drug Development Program PR Newswire
Jul-27-21 10:00AM	Notice of Allowance Issued for Central Nervous System Peptide Technology PR Newswire
Jul-16-21 10:00AM	AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland PR Newswire
Jul-13-21 10:00AM	AIkido Pharma to Attend the Alzheimer's Association International Conference PR Newswire
Jun-23-21 10:00AM	AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease PR Newswire
Jun-05-21 03:16AM	Companies Like AIkido Pharma (NASDAQ:AIKI) Can Afford To Invest In Growth Simply Wall St.
Jun-04-21 09:00AM	AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591 PR Newswire -9.48%
May-20-21 03:24PM	AIkido Pharma Has Pending Data Results on June 4th, with Strongest Balance Sheet in Its History While Trading Below Cash Newsfile
09:15AM	AIkido Pharma Announces Phase 1 Data To Be Presented at the American Society of Clinical Oncology ("ASCO") Annual Meeting PR Newswire
May-19-21 08:30AM	AIKI Featured as Stock to Watch Ahead of Significant Key Milestones Newsfile
May-13-21 09:00AM	AIkido Pharma Inc.: Invitation to the Q2 Virtual Investor Summit Newsfile
08:30AM	AIKI's Near Term Catalyst Approaching this Quarter with Strong Cash Balance Sheet for Strategic Initiatives Newsfile
May-12-21 09:00AM	AIkido Pharma Inc. to Present at the Benzinga Global Small Cap Conference, the Investor Summit Group's Conference, and the LD Micro Invitational Conference PR Newswire -5.45%
May-11-21 09:00AM	AIkido Pharma Inc. Announces First Quarter 2021 Results and Provides Corporate Update PR Newswire
May-06-21 07:00AM	AIkido Pharma Inc. Announces Participation in the Benzinga Global Small Cap Conference Newsfile
Apr-27-21 10:00AM	AIkido Pharma Announces Dr. Rachel Yehuda's Appearance at SXSW PR Newswire
Apr-26-21 09:00AM	AIkido Pharma Announces Inventor and Scientist Dr. Matthew Frieman Joins Scientific Advisory Board PR Newswire
Apr-22-21 09:00AM	AIkido Pharma Announces Withdrawal of S-1 Registration Statement PR Newswire
Apr-16-21 10:00AM	AIkido Pharma Notes Advancement in Radiopharmaceutical Research PR Newswire
Apr-07-21 09:00AM	AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients PR Newswire
Apr-05-21 09:00AM	AIkido Pharma Provides Business Update PR Newswire
Mar-29-21 09:00AM	AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD PR Newswire
Mar-12-21 10:00AM	AIkido Pharma Announces Dr. Matt Frieman's Appearance on This Week in Virology PR Newswire
Mar-04-21 09:00AM	AIkido Pharma Inc. Updates Announcement of Webcast Link for the H.C. Wainwright Global Life Sciences Conference (Virtual Event) PR Newswire -12.93%
Mar-01-21 09:00AM	AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event) PR Newswire +11.76%
Feb-23-21 10:56AM	AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering PR Newswire -16.00%
Feb-22-21 09:00AM	AIkido Pharma Provides Update on its Antiviral Platform, Including the Virus That Causes COVID-19 PR Newswire -7.41%
Feb-19-21 11:10AM	AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock PR Newswire +5.19%
Feb-16-21 10:15PM	AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million PR Newswire -9.36%
04:46PM	AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock PR Newswire
08:30AM	AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment PR Newswire
Feb-03-21 09:00AM	AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board PR Newswire
Feb-02-21 09:00AM	AIkido Pharma Adds Inventor Dr. Neil H. Bander, M.D. to Scientific Advisory Board PR Newswire
Feb-01-21 08:00AM	Aikido Pharma Secures Early Interest in Next Generation Radiotherapy PR Newswire -10.12%
Jan-22-21 01:30PM	AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements PR Newswire
Jan-11-21 08:30AM	Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications GlobeNewswire +7.27%
Jan-06-21 08:00AM	AIkido Pharma Inc. Executes Licensing Agreement for Psilocybin for Cancer Applications PR Newswire +21.99%
Dec-09-20 10:00AM	AIkido Pharma Announces Publication of Artificial Intelligence-Machine Learning Sponsored Research Program for Pancreatic Cancer PR Newswire
Nov-20-20 08:00AM	AIkido Pharma Inc. Announces Results of 2020 Annual Stockholder Meeting PR Newswire
Nov-13-20 09:00AM	AIkido Pharma Inc. Announces Publication of Favorable Peer Reviewed Study of Newly Licensed Antiviral Compounds PR Newswire
Nov-08-20 07:38AM	How Does AIkido Pharma's (NASDAQ:AIKI) CEO Pay Compare With Company Performance? Simply Wall St.
Oct-28-20 01:30PM	AIkido Pharma Inc. Provides Update on Its Next-Generation Chemotherapeutic Treatment DHA-dFdC PR Newswire +7.39%
Sep-18-20 10:00AM	AIkido Pharma Announces Update On Its Use Of Artificial Intelligence PR Newswire
Sep-11-20 10:00AM	AIkido Pharma Inc. Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference) PR Newswire -11.24%
09:00AM	AIkido Pharma Announces Peer-Reviewed Publication of Positive Results from Study of Antiviral Compounds Licensed from University of Maryland, Baltimore PR Newswire
Aug-31-20 05:00PM	LD Micro - 360 Companies Set to Present this Week ACCESSWIRE -6.32%
Aug-18-20 09:00AM	AIkido Pharma Sponsors Survival Study of University of Kentucky Anticancer Drug G4-1 in Exchange for Exclusive Option to License PR Newswire -14.72%
Aug-14-20 09:00AM	AIkido Pharma Inc. to Present at The LD 500 Virtual Conference PR Newswire
Aug-11-20 10:00AM	Option for Treatment for Coronavirus Extended PR Newswire -13.01%
Aug-05-20 09:00AM	LD Micro Announces Preliminary List of Presenters for the LD 500 ACCESSWIRE +7.34%
Aug-03-20 10:00AM	AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements PR Newswire
Jul-09-20 01:31PM	AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus PR Newswire +6.91%
Jun-26-20 10:30AM	AIkido Pharma Inc. Provides Update to Machine Learning Pancreatic Cancer Research PR Newswire +10.50%
May-28-20 10:00AM	AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University PR Newswire
May-19-20 10:00AM	AIkido Pharma Inc. Announces Distribution of Hoth Dividend PR Newswire
May-08-20 05:00PM	AIkido Pharma Inc. Provides Update on Distribution Date for Hoth Dividend Distribution PR Newswire
May-06-20 01:30PM	AIkido Pharma Executes Artificial Intelligence and Machine Learning Research Agreement with Cogia Biotech LTD PR Newswire +7.16%
May-04-20 05:00PM	AIkido Pharma Inc. Provides Update on Anticipated Distribution Date for Hoth Dividend Distribution PR Newswire
Apr-30-20 02:33PM	Notice of Record Date of Hoth Distribution PR Newswire
Apr-21-20 08:30AM	AIkido Pharma Executes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19 PR Newswire -8.26%
Apr-20-20 08:30AM	AIkido Pharma Inc. Sets Record Date for Hoth Distribution PR Newswire
Apr-15-20 01:41PM	AIkido Pharma Inc. Announces Closing of $14.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire +6.75%
Apr-14-20 12:08PM	AIkido Pharma Inc. Announces $14.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire +22.34%
09:00AM	AIkido Pharma Executes Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus PR Newswire
Mar-27-20 05:30PM	AIkido Pharma Inc. Provides Update on Timing of Record Date and Anticipated Distribution Date for Dividend Distribution PR Newswire
Mar-26-20 10:15AM	AIkido Issues Shareholder Update on COVID-19, Dividend, And Path Forward PR Newswire -8.91%
Mar-23-20 08:00PM	AIKido Pharma Inc. Adopts Plan to Preserve Valuable Tax Assets PR Newswire +5.15%
Mar-18-20 12:52PM	Shareholder Update from AIkido Pharma Incorporated on Coronavirus Option PR Newswire -15.54%

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience